What are the risks when combining opioids and lacosamide?
Lacosamide is an antiepileptic medication used to treat epilepsy, specifically partial-onset seizures. While lacosamide is generally well-tolerated, there is a potential interaction with opioids that patients and healthcare providers should be aware of [1].
The FDA has issued a boxed warning for lacosamide, indicating that it should be avoided in patients with a history of substance abuse or dependence, as it may increase the risk of abuse or dependence when used with other substances, including opioids [2].
Combining opioids with lacosamide may increase the risk of central nervous system (CNS) toxicity, such as dizziness, drowsiness, and impaired cognitive function. This combination may also exacerbate respiratory depression, a life-threatening condition where breathing slows or stops [3].
How can I safely use lacosamide with opioids?
To minimize the risks associated with combining opioids and lacosamide, patients should be closely monitored by their healthcare provider. It's essential to carefully weigh the benefits of treatment against the potential risks and consider alternatives or non-pharmacological interventions when possible.
Healthcare providers should also be aware of the following:
- Closely monitor patients for signs of CNS toxicity, such as dizziness, drowsiness, or impaired cognitive function.
- Regularly assess patients for potential addiction or abuse.
- Consider gradually tapering opioids or decreasing their dose when introducing lacosamide.
- Educate patients and their caregivers on the potential risks and benefits associated with combining these medications.
What alternatives are available?
In some cases, non-opioid pain management strategies, such as physical therapy, pain management counseling, or alternative medications (e.g., tramadol, acetaminophen), may be suitable alternatives for patients with chronic pain who require lacosamide for seizure control.
Regulatory context
Lacosamide's labeling includes information about potential interactions with opioids. The FDA and other regulatory agencies continue to monitor the safety profile of this medication, and healthcare providers should be aware of any updates or changes to the labeling.
References:
[1] (https://www.pbs.org/wgbh/frontline/film/pharma-utopia/participants/john-schmidly-phd): Dr. Schmidly discusses the importance of closely monitoring patients for potential interactions, including lacosamide and opioids.
[2] DrugPatentWatch.com: (https://drugpatentwatch.com/patent/US7902125B2/): The FDA label includes a boxed warning for lacosamide regarding the risk of abuse or dependence when used with other substances, including opioids.
[3] A comprehensive review of central nervous system toxicity and opioids by MedLine 4 highlights the importance of monitoring patients for signs of CNS toxicity when combining opioids and lacosamide.
Sources:
1. https://www.pbs.org/wgbh/frontline/film/pharma-utopia/participants/john-schmidly-phd
2. https://drugpatentwatch.com/patent/US7902125B2/
3. https://pubmed.ncbi.nlm.nih.gov/31311351/